List of trial estimands with definitions
| Estimand | Definition |
| Primary outcome | |
| E1 | All-cause mortality |
| Difference (aspirin minus LMWH) in the probability of dying of any cause | |
| Secondary efficacy outcomes | |
| Cause-specific mortality | |
| E2 | Difference in the probability of being observed to die due to PE (adjudication categories a and b) under assigned treatment |
| E3 | Difference in the probability of being observed to die due to PE (adjudication categories a, b and c) |
| E4 | Difference in the probability of being observed to die due to non-PE (categories d or e) related causes of death |
| Non-fatal pulmonary embolism | |
| E5.1 | Difference in the probability of being observed to have a non-fatal PE |
| E5.2 | Difference in the probability of being observed to have a massive non-fatal PE |
| E5.3 | Difference in the probability of being observed to have a submassive non-fatal PE |
| E5.4 | Difference in the probability of being observed to have a clinically significant non-fatal PE |
| E5.5 | Difference in the probability of being observed to have a clinically non-significant non-fatal PE |
| E5.6 | Difference in the probability of being observed to have a segmental non-fatal PE |
| E5.7 | Difference in the probability of being observed to have a non-segmental non-fatal PE |
| Deep vein thrombosis | |
| E6.1 | Difference in the probability of being observed to have symptomatic deep vein thrombosis |
| E6.2 | Difference in the probability of being observed to have proximal deep vein thrombosis |
| E6.3 | Difference in the probability of being observed to have distal deep vein thrombosis |
| Secondary safety outcomes | |
| E7 | Bleeding event |
| Difference in the probability of being observed to have a bleeding event | |
| E8 | Wound complication |
| Difference in the probability of being observed to have a wound complication | |
| E9 | Deep surgical site infection |
| Difference in the probability of being observed to have a deep surgical site infection. | |
LMWH, low-molecular-weight heparin; PE, pulmonary embolism.